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ABSTRACT 
BACKGROUND: Pneumococcal conjugate vaccine (PCV) is now recommended for use in adults 
in the United States. Because vaccination of children with PCVs protects adults from the targeted 
serotypes, local variations in PCV uptake among children could influence the effectiveness of direct 
immunization of adults. The effect of variations in PCV7 and PCV13 uptake in children will be 
compared to assess the possible effectiveness of PCV vaccination in adults.    
 
METHODS: We obtained ZIP Code-level invasive pneumococcal disease (IPD) data from an active 
population-based surveillance system in Connecticut (1998-2013) and ZIP Code-level data on 
immunization with 3+ or 4+ doses of PCV from the state immunization registry. To estimate the 
decline in PCV serotypes in each age group during the PCV7 and PCV13 eras, we fit logistic 
regression models to estimate the proportion of IPD cases in a month caused by a vaccine serotype. 
To determine whether SES factors and/or vaccine uptake was associated with adult IPD cases we fit 
logistic regression models to estimate the proportion of IPD cases among adults >40 years that was 
caused by PCV-targeted serotypes. Covariates included ZIP Code-level socioeconomic indicators 
(e.g. percent black, income), percent of the population that received at least 3 (3+) or at least 4 (4+) 
doses of PCV (mean centered), and a linear spline to control for the average rate of decline across 
all ZIP Codes. The data were split into the 2000-2009 PCV7 era and the 2010-2013 PCV13 era to 
compare the effect of the two vaccines. In the PCV7 era we selected the best model for estimating 
the proportion of IPD cases among adults >40 years that was caused by PCV7-targeted serotypes by 
ranking the models by AIC score. In the PCV13 era we conducted AIC based model averaging to 
estimate the proportion of IPD cases among adults >40 years that was caused by PCV13-targeted 
serotypes.  
 RESULTS AND SIGNIFICANCE: The PCV7 serotypes declined rapidly as causes of IPD in 
children while the decline was slower and delayed in adults. A similar pattern was seen in the 
PCV13 serotype decline. ZIP Codes that had a higher proportion of children that did not complete 
the four-dose PCV7 series had a higher proportion of adult IPD cases caused by PCV7 serotypes. 
This trend is not yet evident in adults during the PCV13 era. Local variations in PCV uptake might 
influence the effectiveness of PCVs in preventing pneumococcal disease in adults.  
INTRODUCTION 
Pneumococcal conjugate vaccines (PCVs) have been used in children in the United States 
for over a decade. Introduction of the original conjugate vaccine (PCV7) was associated with rapid 
declines in invasive pneumococcal disease (IPD) caused by the PCV7-targeted serotypes among 
both children (who received the vaccine) and adults (who did not receive the vaccine) [1-4]. After 
introduction of the PCV7 vaccine in 2000, increases in the number of IPD cases caused by some 
nonvaccine pneumococcal serotypes was noted. A 13-valent vaccine (PCV13) was introduced in 
February 2010, which included the seven original serotypes plus six additional serotypes 
responsible for 63% of IPD cases in children during the post-PCV7 era [5, 6]. The new 13-valent 
vaccine was predicted to prevent 106,000 IPD cases and save $11.6 billion compared to PCV7 over 
a 10-year period in the United States [7].  
There are still important questions about how to best protect adults from pneumococcal 
disease. Recently, the Advisory Committee on Immunization Practices (ACIP) recommended 
routine use of PCV13 among adults aged ≥65 years in the United States [8]. However, because 
adults are indirectly protected when children receive PCVs, the fraction of IPD cases in adults that 
can be prevented declines over time, and it is not clear whether direct immunization of adults with 
the same vaccine would be effective [9, 10].  
Little is known about how vaccine uptake rates with 3+ or 4+ doses, transmission intensity, 
and serotype distributions vary between communities. It is possible that in high population density 
settings, adults maintain transmission of PCV-targeted serotypes due to decreased exposure to 
young vaccinated children. Previous studies have found that low PCV7 uptake is associated with 
being black or Hispanic, receiving vaccinations from public health providers, and low household 
income [11, 12]. Variations in these factors could result in geographic pockets that have a higher or 
lower fraction of IPD cases caused by vaccine-targeted serotypes. In the pre-vaccine period, IPD 
incidence has been shown to be higher in census tracts with more poverty, and greater numbers of 
blacks [13-15]. The serotype distribution is also different for census tracts with greater poverty and 
higher percentage black [13]. The pre-existing IPD trends and trends in vaccine uptake could 
influence the impact of direct immunization of adults with PCVs.  
We tested the hypothesis that in the years following vaccine introduction, PCV-targeted 
serotypes caused a disproportionate fraction of IPD cases among adults living in communities with 
a lower socioeconomic status (SES) or lower uptake of PCVs among children. We evaluated this 
hypothesis using state-wide data from Connecticut on IPD incidence among children and adults and 
data on PCV7 and PCV13 uptake among children. 
 
METHODS 
All analyses were split by the PCV era for comparison. We assumed that the PCV7 era 
encompassed data from 2000-2009, while the PCV13 era covered 2010-2013. 
 
Data Sources 
Data on invasive pneumococcal cases were collected from the Active Bacterial Core 
surveillance system for the state of Connecticut for the period from 1998 to 2013 [4]. For each case, 
we had data on the month and year of sampling, the serotype, and the age group (<5, 5 to 17, 18 to 
39, 40 to 64, and over 65 years). IPD case data for 2014 was not yet available at the time of this 
analysis.  
Data on PCV uptake by ZIP Code were obtained from the Connecticut Immunization 
Registry and Tracking System (CIRTS). CIRTS is a mandatory, opt-out registry used to keep 
permanent records of the vaccination of children up through the age of two years. Approximately 
10% of families opt out of the registry, and the other missing data constitute loss to follow-up (e.g. 
move out of state) or incomplete records. The data were aggregated by birth cohort and ZIP Code, 
and we obtained the total number of children in the registry in each strata and the number of 
children who received 3+ or 4+ doses of PCV. To estimate the total coverage of PCV in each month 
and ZIP Code among children 12-59 months of age, we used a cohort approach similar to Nuorti et 
al [11]. We assumed that the birth rate was constant over the year and that all children who received 
3+ or 4+ doses of vaccine by age 2 were vaccinated according to schedule.  
The CIRTS database cannot distinguish PCV7 doses from PCV13 doses in the years 
immediately after the implementation of PCV13. We estimated the switch over from PCV7 to 
PCV13 in 2010 using U.S.-wide calculations from Schuck-Paim et al [16]. Schuck-Paim calculated 
the switch over from PCV7 to PCV13 using physicians’ office claims data from January 2008 to 
May 2012.  We multiplied the number of children in CIRTS receiving 3+ or 4+ doses of PCV 
vaccine by the PCV13 uptake estimate in Schuck-Paim et al. We filled in the PCV13 vaccine 
uptake estimates from June 2012 to December 2013 using May 2012 uptake estimates, therefore 
assuming that the rest of the PCV13 era’s vaccine uptake was equal to May 2012.  
Because we wanted to focus on the importance of variations in vaccine uptake between ZIP 
Codes, we mean centered the vaccine uptake variables—for each date, we subtracted the mean 
uptake of 3+ or 4+ doses of PCV for the state of Connecticut from the uptake of 3+ or 4+ doses in 
each ZIP Code. These new mean-centered variables are centered around 0 at each date (Figure S1, 
S2). To quantify the additional benefit of completing the full 4 dose series, we subtracted the 4+ 
dose uptake variable from the 3+ dose uptake variable and then subtracted the mean at each date 
from this variable. Thus, this variable indicates whether the percent of children in a ZIP Code that 
received 3 doses but did not receive a 4th dose differed from the state average.   
 Demographic data for each ZIP Code tabulation area (ZCTA) in Connecticut were obtained 
from the U.S. Census Bureau. We collected information on SES indicators such as the percentage 
of the population that was black, white, or Hispanic, income per capita, population density, and 
population size in each ZIP Code.  
The Human Investigation Committees at Yale School of Medicine and the Connecticut 
Department of Public Health approved this study. 
 
Estimating the rate of decline of vaccine serotypes in the PCV7 era and the PCV 13 era  
We estimated the overall rate of decline of vaccine serotypes in each age group. To estimate 
the decline in PCV7 serotypes, we fit separate logistic regression models where the outcome was 
the proportion of cases of IPD in a given month caused by a vaccine serotype. The typical approach 
would be to fit a trend line to these data to estimate this decline over time. However there is 
uncertainty about exactly when this decline should begin, and the time of the decline might vary 
between age groups. To capture the uncertainty, we used a linear spline, where the location of the 
spline knot (the change point) was unknown. This provides a robust estimate for the rate of the 
decline and an estimate for when the decline begins in each age group. The potential covariates for 
the PCV7 logistic regression were a series of linear splines that had a value of 0 prior to a change 
point and then changed (log)-linearly after the change point. We fit 144 separate regressions, each 
of which had a single spline with the knot in a different month between 1998 and 2009.  
In the PCV13 era we used the linear spline method from the PCV7 era (which estimated the 
change in slope over time), as well as another statistical method that measured if there was an 
immediate change in mean. The linear spline method modeled a series of linear splines that had a 
value of 0 prior to a change point and then changed (log)-linearly after the change point. This 
models a constant rate of decline that occurs over a longer time period. However, because in the 
PCV13 era uptake of PCV13 occurred more rapidly than in the PCV7 era (Figure 2), we 
anticipated that the gradual spline method might not fit the data well in the PCV13 era. Therefore, 
we decided to include another method that accounted for an immediate decline in PCV13 serotypes. 
The immediate decline method uses a dummy variable to test for an immediate change in mean. We 
also created a new variable to account for pre-existing time trends before PCV13 vaccine 
introduction.  
This meant that we had four different logistic regression model types to test the rate of decline of 
vaccine serotypes in the PCV13 era (Mean Change without Secular Trent, Mean Change with 
Secular Trend, Slope Change without Secular Trend, and Slope Change with Secular Trend). The 
fifth type of logistic regression we used was a null model that modeled the odds that there was no 
change in vaccine serotypes in the PCV13 era (Null Model).       
To estimate the decline in PCV13 serotypes in the PCV13 era for each age group, we tested 
the five different types of logistic regressions, which modeled the odds that an IPD case in a given 
month was caused by a PCV13 vaccine serotype. We fit 96 separate regressions for each model 
type, in order to test a single spline with the knot in a different month between 2006 and 2013. This 
was repeated for each of the five age groups resulting in a total of 2,400 logistic regressions (480 
per age group).    
The fit of each of the models in the PCV7 and PCV13 era was evaluated using the Akaike 
Information Criterion (AIC). The AICs were used to generate a weight for each model (better-
fitting models had higher weights) and to estimate the probability of the decline beginning in any 
given month [17, 18]. This provides a distribution of likely values for the change point, and the 
mean and 2.5th and 97.5th percentiles of this distribution gives the credible interval for the most 
likely change point for each age group. The rate of decline per year from each of the models was 
estimated as 100*(exp(Coeff_trend*12)-1). To get an estimate of the rate of decline per age group 
and the 95% credible intervals in the PCV7 era, this value was averaged across the all candidate 
models in the PCV7 era, with the weight determined by the AIC score [19]. In the PCV13 era, we 
summed the weights of each model type (determined by AIC score) for each age group to find 
which model type best described the decline in vaccine serotypes for that age group in the PCV13 
era (Table 7).   To get an estimate of the rate of decline per age group and the 95% credible 
intervals in the PCV13 era, this value was averaged across the all the 96 different spline models 
from the best model type with the weights determined by the AIC score.  
 
Factors associated with PCV uptake in children  
To evaluate factors associated with variations in vaccine uptake, we fit a logistic regression 
model. The outcome variable in this univariable analysis was the proportion of children in the 
CIRTS registry within a given ZIP Code that received 3+ doses, 4+ doses, or only 3 doses of PCV 
divided by the total number of children in the CIRTS registry for that ZIP Code. The covariates 
were ZIP Code-level SES factors, including proportion of the population in the ZIP Code that was 
black or Hispanic, proportion under the age of 5, logarithm of income per capita, and logarithm of 
population density (overall, and under age 5). This particular analysis used vaccine uptake data 
from a single date (January 1, 2006 for PCV7 era, and Jan 1, 2012 for PCV13 era), with the 
assumption that the relative differences in uptake between ZIP Codes was consistent over time. 
This date was chosen for the PCV7 era because the vaccine program had “matured” by this point 
(i.e. the entire <5 year old cohort should have been vaccinated according to schedule). The PCV13 
date was chosen as it was the center point in time for the four years of data. A significant coefficient 
value (p<0.05) for the SES variable was taken as evidence that vaccine uptake differed by SES 
characteristic in a ZIP Code.  
 
Exploratory analysis for relationship between vaccine uptake and serotype distribution 
To evaluate the link between vaccine uptake and the proportion of IPD cases caused by a 
PCV serotype, we divided ZIP Codes into five groups for each year (quintiles) based on uptake of 
4+ doses. We then compared the average uptake of PCV for each of these quintiles in each year and 
the observed proportion of IPD cases caused by PCV serotypes in each of these quintiles. 
 
Factors associated with variations in proportion of IPD cases in adults caused by PCV7 serotypes  
To determine whether PCV7 uptake or SES factors were associated with the proportion of 
disease cases caused by PCV-targeted serotypes, we fit a logistic regression. The outcome variable 
was the proportion of IPD cases at a given date and ZIP Code that was caused by a PCV7 serotype. 
For this analysis, we focused only on adults >40 years of age (40-64 and 65+ age groups). Based on 
the results of the change point analyses, all models in the PCV7 era included a linear spline (with a 
knot in June 2001 for PCV7) to capture the average decline in PCV serotypes across all ZIP Codes. 
The model with the lowest AIC score was considered the model with the best fit to the IPD data in 
adults.  
 
Factors associated with variations in proportion of IPD cases in adults caused by PCV13 
serotypes  
In the PCV13 era, we tested all linear splines from January 2006 to December 2013. We 
decided to test all linear spline since the 95% CIs for the change points in the adult age groups were 
very wide, indicating much less certainty in the change points than in the PCV7 era. We tested the 
40-64 and 65+ age groups together and separately (Tables 4-6), as the change point analysis 
indicated that the 65+ age group experienced a slightly quicker decline in PCV13 serotypes. The 
ZIP Code-level covariates were uptake of 3+ doses of the vaccine (mean-centered for each date), 
uptake of 4+ doses of the vaccine (mean-centered for each date), and only 3 doses of the vaccine 
(mean-centered for each date), proportion of the population of the population that was black, and 
logarithm of population density (overall, and over age 65). We chose these covariates as they were 
the best predictors of IPD cases in the PCV7 era. We fit 16 models with different combinations of 
covariates and splines. Because there was uncertainty about which SES variables to include, and 
how to model the change in IPD cases over time we averaged all our models together in a Bayesian 
model averaging approach.   
To summarize the beta estimates for each covariate in the model, we averaged all 16 
regression models across the model types using the covariate weights calculated from the AIC 
scores. We assumed that there was a 0.5 prior probability that there was no change point in the data 
(null model), and set the prior probability for the models with a change point to be 0.5/16. All of the 
models tested and their associated AIC can be found in Table S1-S5.  
 
Evaluating fit of models identified in the PCV7 and PCV13 eras to determine factors associated 
with variations in proportion of IPD cases in adults caused by PCV13 serotypes  
To evaluate the fit of the best model/averaged model in PCV7 and PCV13 eras, we divided 
the ZIP Codes into five groups (quintiles) in each year by the predicted proportion of IPD cases 
caused by PCV serotypes. Within each quintile, we estimated the mean predicted value and the 
observed proportion of IPD cases caused by PCV serotypes for that year. The observed and 
expected values of these quintiles should be similar in all years if the model fits well.   
 All models were fit using PROC GENMOD (SAS V9.3, Cary, NC) 
 
Sensitivity analysis for factors associated with variations in proportion of IPD cases in adults 
caused by PCV13 serotypes 
 The PCV7 era had a significant advantage when testing factors associated with variations in 
proportion of IPD cases in adults caused by PCV7 serotypes, as there was 10 years of post-vaccine 
data to analyze. 2000 and 2010 are considered transition years in the data as they are vaccine 
introduction years, and both years have very low vaccine coverage levels. This means that these 
years are not very useful for analysis. Therefore, the PCV13 era only had three years of post-
vaccine data to analyze while the PCV7 era had nine years of post-vaccine data. As a result we are 
less confident in the analyses from the PCV13 era than the PCV7 era. Our results from the logistic 
regressions that tested the factors associated with variations in proportion of IPD cases in adults 
caused by PCV13 serotypes, were different from the factors associated in the PCV7 era. In the 
PCV7 era we found that failure to complete all 4 doses of PCV7 was a predictor of adult PCV7-
targted serotype cases. However this was not evident in the PCV13 data, but perhaps this was due 
to lack of vaccine uptake data. In order to determine when we would have been able to detect the 
effect of PCV7 vaccination, we restricted the years of PCV7 vaccine uptake and IPD data 
sequentially. We retested the logistic regression model beginning with only one year of PCV7 data, 
and worked back up to 7 years. This provided an estimate for how many years of data were needed 
before PCV13 uptake is an important predictor.  
  
RESULTS 
 
Characteristics of IPD and vaccine data 
From 2000 to 2009 during the PCV7 era, there were 5,838 cases of IPD captured in our 
database. Of these cases, 709 occurred among <5 year old children, 226 among 5-17 year olds, 581 
among 18-39 year olds, 1,947 among 40-64 year olds, and 2,375 among those 65+. Across all 12 
years of data collection in the PCV7 era, 3,525 cases were caused by non-PCV7 serotypes, while 
2,313 cases were caused by PCV7 serotypes. From 2010 to 2013 during the PCV13 era there were 
1,258 cases of IPD captured in the database. Of these PCV13 era cases, 69 occurred in the <5 year 
old children, 35 among the 5-17 year olds, 94 among the 18-39 year olds, 476 among the 40-64 
year olds, and 585 among the 65+ age group. Of these 1,258 total cases, 846 cases were caused by 
non-PCV13 serotypes and 412 cases were caused by PCV13 serotypes.   
 By December 2009 (end of the PCV7 era), 94.7% of the children in the vaccine registry 
were vaccinated with 3+ doses of PCV7, and 88.4% were vaccinated with 4+ doses of PCV7. These 
estimates from CIRTS are similar to coverage estimates from the National Immunization Survey 
[20]. Using the U.S. estimated coverage for PCV13 [16], we estimated that 89.6% of children were 
vaccinated with 3+ doses of PCV13, and 81.83% with 4+ doses of PCV13 vaccine by May 2012. 
According to NIS, 94.8% of children in Connecticut were vaccinated with 3+ doses of a PCV and 
91.1% were vaccinated with 4+ doses of a PCV by December 2012. The NIS database does not 
distinguish between PCV7 and PCV13, so we would expect the NIS coverage estimates to be 
higher than our PCV13 calculations since the NIS database includes both PCVs in estimated 
coverage. After comparing the NIS estimated coverage and our calculated PCV13 coverage, we can 
see that the switch over to PCV13 almost complete by 2012.    
 Changes in the proportion of IPD cases caused by PCV7 and PCV13 serotypes 
 After PCV7 was introduced in 2000, the proportion of IPD cases caused by the seven 
targeted serotypes declined in all age groups (Figure 1A). This decline was evident among children 
<5 years in early 2000, while the decline was delayed by ~17 months among adults 40-64 and 65+ 
years of age (Figure 1B).  The decline among children aged 5-17 was further delayed, until late 
2002. The rate of decline of the PCV7 serotypes among the <5 year olds was significantly more 
rapid than among the adults.  The rate of decline among children under 5 was -62.7% per year (95% 
CI: -55.4, -68.8%) compared with -36.2% (95% CI: -32.0, -40.3%) and -37.0% (95% CI: -32.7, -
40.98%) per year among 40-64 and 65+ year olds, respectively. By 2008, <8% of IPD cases in 
adults ages 40+ were caused by PCV7 serotypes  
A similar pattern of PCV13 serotype decline was seen after the introduction of PCV13 in 
February 2010. We estimated the percent decline in PCV13 serotypes in each age group using the 
model type with the highest weight as calculated from AIC score (Table 7). The decline in children 
<5 started in May 2010, and was best described by the Mean Change without Secular Trend model 
(immediate change with a constant percent decline across all years). The PCV13 serotypes declined 
-81.7% (95% CI: -88.8, -69.8%) during the PCV13 era for those <5 years old. The decline in the 
40-64 age group started in January 2011, and was best described by the Slope Change without 
Secular Trend model (linear percent decline per year). The decline among adults 40-64 years old 
was -36.1% per year (95% CI: -58.3, -1.9%). The decline in the 65+ age group was slightly earlier 
than the 40-64 year olds, starting in August 2010, and was also best described by the Slope Change 
without Secular Trend model. The decline among adults 65+ was -28.9% per year (95% CI: -43.7, -
10.11%) (Figure 1C, D).   
Variations in PCV uptake by ZIP Code 
Uptake of 3+ and 4+ doses of PCV7 varied substantially between ZIP Codes (Figure 2B). 
These differences in uptake were minimized during the PCV13 period (Figure 2D).  In univariable 
analyses, ZIP Codes with lower uptake of 3+ or 4+ doses of PCV7 and PCV13 were significantly 
more likely to have a higher percentage of the population that was black or Hispanic, a higher 
percentage of the population that was under 5 years of age, and a higher overall population density 
and population density of children <5 years of age (Table 1). ZIP Codes with lower uptake of 3+ or 
4+ doses of PCV13 were also significantly more likely to have a lower per capita income. This 
association with per capita income was not seen in the PCV7 era.   
  
Factors associated with variations in proportion of IPD cases in adults caused by PCV7 serotypes  
ZIP Codes with lower-than-average PCV7 uptake (3+ or 4+ doses) at a given date tended to 
have a higher proportion of IPD cases caused by PCV7 serotypes (Figure 3A, Table 3). Variables 
associated with lower SES (e.g. population density) were not significantly associated with the 
serotype distribution (Table 3, S1). In the best-fit multivariable model (Table 3), having a higher 
proportion of IPD caused by PCV7 serotypes was associated with a higher-than-average percent of 
children failing to receive the 4th dose after having received 3 doses of PCV7. As the gap between 3 
and 4 dose coverage increased by 10%, the odds of IPD caused by a PCV7 serotype case increased 
by 54.3% (95% CI: 20.2%, 98.2%). There was also a non-significant association between uptake of 
3+ doses of PCV7 and serotype distribution (Table 3). Additionally, the 40-64 year old category 
had a 15.1% lower odds (95% CI: -33.17%, 6.30%) of IPD caused by a PCV7 serotype compared to 
the 65+ age category. This model accurately captured variations in the proportion of IPD cases 
caused by PCV7 serotypes for all years (Figure 4). Four years after vaccine introduction, the model 
predicted that 16-25% of cases would be caused by PCV7 serotypes. By 2009, the model predicted 
that just 3-5% of cases would be caused by PCV7 serotypes. Several other models also fit the data 
well (i.e. AIC score within 2 points of best model). All of these models included age group, uptake 
of 3+ doses of PCV7 (mean centered), and either uptake of 4+ doses of PCV7 (mean centered) or 
uptake of only 3 doses PCV7 (mean centered). Population density (log-transformed) was also 
included in several of the best-fit models (Table 3, Table S1), but did not affect the estimates of the 
importance of vaccine uptake (Table 3).  
 
Factors associated with variations in proportion of IPD cases in adults caused by PCV13 
serotypes  
There was no discernible relationship between PCV13 uptake and proportion of IPD cases 
in adults caused by PCV13 serotypes (Figure 3B). By December 2010, only 35% of Connecticut 
had switched to PCV13 from PCV7, and it was not until late 2011 that high levels of PCV13 
coverage were achieved. Most of the variables associated with lower SES were not significantly 
associated with the serotype distribution for any of the model types, except for percentage black in 
a ZIP Code. (Table 4, 5). There was no association between PCV13 uptake and serotype 
distribution across all age category models (Table 4-6). The only significant predictor of adult 
PCV13 serotype cases was percentage black in a ZIP Code, and this variable was significant for the 
40-64 age category models, and the combined age category models but not for 65+ age category 
models. For every 10% increase in the percentage black in a ZIP Code, the odds of a PCV13-
targeted IPD case in the 40-64 age group decreased by -22.11% (95% CI: -28.99, -14.53), while the 
odds for the 65+ age group decreased by -2.79% (95% CI: -11.24, 6.46). In the combined age group 
model, the odds decreased by -17.64 (95% CI: -23.37, -11.49).    
These models accurately captured the decline in proportion of IPD cases caused by PCV13 
serotypes over time (Figure 5), but did not accurately estimate variations in the proportion of IPD 
cases within a given year. For the PCV13 era we used PROC CORR to find the Pearson Correlation 
Coefficient between the observed proportion of IPD cases caused by PCV13 serotypes, and the 
predicted mean value. The 40-64 age category models and the combined age category models had 
the best fit to the data of the 3 age category models. The 40-64 year old age category models had a 
correlation coefficient of 0.77, the 65+ age category models had a correlation coefficient of 0.63, 
and the combined age group models had a correlation coefficient of 0.78. All the correlation 
coefficients were significant at the p<0.05 level. The decline in proportion PCV13 cases over time 
is clear, but there is a little separation between the quintiles of data. The correlation coefficients 
indicate that the 65+ age group was not as well described by the logistic regression models as the 
40-64 years olds, and the combined age groups.    
 
Sensitivity analysis for factors associated with variations in proportion of IPD cases caused by 
PCV7 serotypes 
After sequentially restricting the data in the PCV7 era, we determined that it took 6 years 
before PCV7 vaccine uptake was a significant predictor of adult PCV7-targeted  IPD cases. In the 
early years after vaccine introduction, demographic variables (in particular percentage black) were 
better predictors than vaccine uptake. The best fit model identified using the 2000-2009 data range 
was not the lowest AIC scored model until testing data from 2000-2006. Vaccine uptake is not a 
significant predictor in any model until after 2002.  
 
 
DISCUSSION 
PCVs are now in use among children around the world, and many countries are considering 
whether adults should also receive the same vaccine. Adults receive strong indirect protection in 
settings with high uptake of PCVs among children. In our data, only a small fraction of IPD cases in 
adults were caused by PCV7 serotypes after a decade of vaccine use in children. In such settings, 
immunizing adults with the same vaccine as children might not be justified. However, our data 
suggest that local variations in vaccine uptake among children might allow PCV7-targeted 
serotypes to persist as causes of disease in adults when the uptake levels are not maximal. In 
locations where vaccine uptake is less complete, either due to vaccine refusals or deficiencies in the 
public health system, local variations in PCV7 uptake in children might influence the serotype 
distribution in adults and could factor into decisions about whether to also immunize adults with 
PCVs. 
In the PCV13 era we saw that demographic variables such as percentage black were better 
predictors of pockets of adult IPD PCV13-targeted cases. When looking at the results of the 
sensitivity analysis for factors associated with variations in proportion of IPD cases caused by 
PCV7 serotypes, we can see that in the early years after PCV7 introduction demographic variables 
were better predictors than vaccine uptake until about 2006. In the PCV13 era the only significant 
predictor of IPD PCV13-targeted case was percentage black in a ZIP Code. Percentage black in a 
ZIP Code was significant predictor for the 40-64 and combined age groups, but not the 65+ age 
group (Table 4, Table 5). There is a 3-22% decrease in adult PCV13-targeted IPD cases for every 
10% increase in percentage black in a ZIP Code, for the adult age groups. This negative association 
may be due to serotype replacement effects from the PCV7 era. After the introduction of PCV7, 
blacks experienced higher levels of serotype replacement, and had increases in the non-PCV7 
serotypes beyond that of whites. By 2009, a higher proportion of IPD in whites was caused by 
PCV13-targeted serotype than in blacks [14, 21]. Therefore, serotype replacement may have 
affected the racial groups differently, and serotype distribution may differ for low SES groups as a 
result. PCV13 may not be ideally designed to eliminate the most common serotypes in blacks, and 
may be better suited to the serotype distributions in whites.   
The sensitivity analysis for identifying how soon PCV7 uptake becomes an important 
predictor in PCV7 period also supports the idea that racial composition of a ZIP Code is important 
in the early years of vaccine introduction. We found that in the first 4 years of PCV7 introduction, 
the percent black in a ZIP Code was an important predictor of adult PCV7-targeted IPD cases. 
These results support the idea that we may see the same association between local variations in 
vaccine uptake in children and the persistence of PCV13-targeted serotypes among adults as in the 
PCV7 era. We may be capturing the early association where race is an important early predictor of 
persistence of PCV13-targeted serotypes among adults. 
Uptake of PCVs in children in Connecticut has been high overall, with ~95% of children in 
the CIRTS registry having received at least 3 doses of PCV7. Similarly, 89.6% of children in the 
CIRTS registry received at least 3 doses of PCV13 in 2013. Uptake of PCV13 across Connecticut 
was faster and overall there was less difference in uptake between the ZIP Codes compared to the 
PCV7 era (Figure 2D). Uptake of 4 doses of PCV lagged behind in some ZIP Codes in 
Connecticut. In particular, areas with lower SES indicators tended to have lower uptake of PCV7 
and PCV13. Outreach to low income communities may be needed to improve 4+ dose vaccination 
rates in these areas.    
Given the costs associated with PCVs, there is substantial interest in considering alternative 
dosing or reduced-dose schedules for PCVs. Because much of the benefit derived from PCVs 
results from indirect protection, it is important to consider how dosing schedules might influence 
such indirect effects.  A systematic review of dosing schedules on rates of carriage and disease [22, 
23] suggested that a variety of dosing schedules can indirectly protect adults. The review suggested 
that in the first year of life, 3 doses of PCV had a greater effect on the risk of colonization than 2 
doses. There were not clear differences between dosing schedules on the magnitude of the indirect 
effect against IPD or pneumonia. Our results suggest that the 4th dose of PCV7 might have an 
additional benefit beyond that provided by 3 doses of vaccine in indirectly protecting adults against 
IPD. Our study has the advantage of being able to examine this question in the context of a single 
study population over time. We found that ZIP Codes with a high percentage of children that failed 
to complete the 4-dose PCV7 series had a significantly higher proportion of IPD cases in adults 
caused by PCV7 serotypes. This association persisted after controlling for demographic 
characteristics, which are themselves associated with variations in PCV uptake. This type of 
analysis will need to be repeated in an independent setting to evaluate the potential impact of this 
4th dose on protecting adults from IPD. The relationship between PCV uptake in children and 
disease rates in adults may or may not translate to the post-PCV13 period. Our sensitivity analysis 
indicates that at least six years of data are needed before the impact of PCV uptake on the 
proportion of IPD cases caused by the vaccine serotypes in adults can be assessed; thus, there may 
not be enough data available yet in the PCV13 era to compare the two periods. So far, the best 
model describing the decline in PCV7 serotypes has not been a good fit for the PCV13 data. In 
particular, the 65+ age category is not well described by this best model from the PCV7 era. More 
data are needed to determine if the 4th dose of PCV13 provides additional protection over the 3rd 
dose, as in the PC7 era. 
Our results have some limitations. This is an observational study with ecological data. As a 
result, associations between vaccine uptake and serotype distribution at the ZIP Code level should 
be interpreted with caution. While we control for demographic characteristics in our multivariate 
model, we cannot exclude the possibility that other unmeasured confounders impact serotype 
distribution at the ZIP-Code level. For instance, it is possible that higher rates of co-morbidities in 
some communities might increase the risk for developing vaccine-serotype disease. Our approach 
of analyzing the proportion of disease cases caused by vaccine serotypes, rather than incidence, 
partly controls for this issue by implicitly adjusting for differences in overall disease risk between 
communities. This assumes that the factors that lead to persistence of vaccine serotypes are the 
same factors that influence the risk for disease caused by non-vaccine serotypes. The model 
averaging approach used to determine the best models in the PCV13 era is more robust than the 
calculations from the PCV7 period, which does not have the additional averaged data. However 
when setting up our prior probabilities for the 16 models with a change point, we assumed that the 
prior probability was the same for all these models. This may not have been the case, and some 
models should have been weighted more or less heavily.  
There were several important limitations regarding the CIRTS data. It was difficult to 
estimate the switch over from PCV7 to PCV13 as the CIRTS database does not distinguish between 
PCV7 and PCV13, so we do not have exact data on ZIP-Code level uptake of PCV13. Furthermore, 
the switch over period in Connecticut may not be perfectly described by the national data used to 
estimate it, as the uptake pattern in Connecticut may have been different. Not every child in 
Connecticut is represented in the CIRTS immunizations registry. The vaccination status of ~15% of 
the children is unknown, so our vaccine uptake estimates may overestimate the true coverage level 
in the ZIP Codes if the children not included in CIRTS are less likely to have been vaccinated with 
PCV. Additionally, the CIRTS registry primarily follows children through age 2, so if the 4th dose 
of PCV is delayed beyond age 2, it will not be captured in the registry. If some populations are 
more likely to delay the 4th dose, this could impact the interpretation of our results. We also only 
had 4 years of data to analyze for the PCV13 period, as the 2014 vaccine uptake data were not yet 
available. 
In conclusion, we found that vaccine uptake varies with SES factors [24] and that pediatric 
vaccination affects serotype patterns in adults [25-27]. Our findings are unique in that after 
controlling for SES factors and the overall trend associated with vaccine introduction, we identified 
an association between local variations in vaccine uptake in children and the persistence of PCV7-
targeted serotypes among adults. This underscores the importance of maintaining high coverage of 
vaccines among the pediatric population for protecting individuals of all ages. It remains to be seen 
if this association is mirrored in the PCV13 era, as more data are needed to analyze this association.   
 
 
 
 
 
 
 
 
 
 
 
Table 1. Factors associated with higher percent vaccinated with 3+ or 4+ doses of PCV7 in 
Connecticut. 
Univariable Model Variables† Odds Ratio 95% CI 
Uptake 3+ Doses Percent Black† 0.55 0.50, 0.60 
 Percent Hispanic†  0.82 0.74, 0.91 
 Percent Under 5† 0.17 0.08, 0.37 
 Log Density* 0.48 0.42, 0.54 
 Log Density 
Under 5* 
0.55 0.50, 0.61 
 Log Income* 1.09 0.92, 1.30 
    
Uptake 4+ Doses Percent Black† 0.80 0.74, 0.85 
 Percent Hispanic†  0.86 0.81, 0.91 
 Percent Under 5† 0.27 0.17, 0.50 
 Log Density* 0.73 0.68, 0.80 
 Log Density 
Under 5* 
0.76 0.71, 0.82 
 Log Income* 1.19 1.04, 1.34 
    
Uptake Only 3 
Doses 
Percent Black† 0.95 0.90, 1.01 
 Percent Hispanic†  1.03 0.96, 1.10 
 Percent Under 5† 1.49 0.82, 2.71 
 Log Density* 0.96 0.88, 1.05 
 Log Density 
Under 5* 
0.98 0.90, 1.05 
 Log Income* 0.86 0.76, 0.99 
†Change in odds per 10-percentage point change in socioeconomic variable 
*Change in odds per 1 log change in socioeconomic variable   
 
 
 
 
 
 
 
 
Uptake 3+ Doses Percent Black† 0.98 0.97, 0.99 
 Percent Hispanic†  1.05 1.01, 1.07 
 Percent Under 5† 0.64 0.55, 0.73 
 Log Density* 1.03 1.01, 1.03 
 Log Density 
Under 5* 
1.02 1.01, 1.03 
 Log Income* 1.17 1.12, 1.23 
    
Uptake 4+ Doses Percent Black† 0.93 0.92, 0.94 
 Percent Hispanic†  0.93 0.90, 0.95 
 Percent Under 5† 0.46 0.40, 0.52 
 Log Density* 0.95 0.94, 0.97 
 Log Density 
Under 5* 
0.95 0.94, 0.96 
 Log Income* 1.34 1.29, 1.39 
    
Uptake Only 3 
Doses 
Percent Black† 1.14 1.13, 1.16 
 Percent Hispanic†  1.32 1.28, 1.27 
 Percent Under 5† 3.31 2.72, 4.01 
 Log Density* 1.19 1.16, 1.21 
 Log Density 
Under 5* 
1.18 1.16, 1.21 
 Log Income* 0.61 0.57, 0.65 
†Change in odds per 10-percentage point change in socioeconomic variable 
*Change in odds per 1 log change in socioeconomic variable   
Table 2. Factors associated with higher percent vaccinated with 3+ or 4+ doses of PCV13 in 
Connecticut. 
Univariable Model Variables Odds Ratio 95% CI 
For the full list of models tested and their AIC scores, see Table S1 
† Change in odds per 10-percentage point change in PCV7 uptake 
* Odds of a 40-65 year old compared to the odds of a 65+ year old 
** Change in odds per year after June 2001 
 
 
Table 3. Factors associated with having a higher proportion of invasive pneumococcal disease cases caused by a PCV7-  
targeted serotype.  
Model Variables Percent 
change*** 
 
95% CI 
Best Model    
 Only 3 Doses (Mean Centered)† 54.30 20.20, 98.20 
 
  3+ Doses (Mean centered)† -15.70 -33.24, 6.30 
 
 Age Category* -1.60 -3.10, -0.20 
 
 Linear Trend ** -36.16 -38.12, -30.23 
    
Alternative models    
Bivariable  Linear Trend ** 
 
-36.16 -38.12, -30.23 
 Only 3 Doses (Mean Centered)† 46.96 14.91, 87.95 
     
Bivariable  Linear Trend ** 
 
-36.16 -38.12, -30.23 
 Age Category* -1.19 -2.76, 0.10 
    
 
-38.12, -30.23   Linear Trend **  -36.16 
 3+ Doses (Mean Centered)† -9.70 -27.96, 13.20 
    
Bivariable  Linear Trend ** -36.16 -38.12, -30.23 
 Log-population density*** 5.01 -1.64, 12.11 
    
Multivariable Only 3 Doses (Mean Centered)† 50.23 16.07, 94.45 
3+ Doses (Mean centered)† -14.36 -32.36, 8.55 
 
 Age Category* -1.69 -3.15, -0.02 
 Linear Trend** -36.16 -38.12, -30.23 
 Log-population density*** 2.81 -4.04, 10.14  
****Change in odds per 1 log change in socioeconomic variable  
 
 
 
Age Category*     53.83                               (-35.20, 265.18) 
     
 
3+ Doses (Mean Centered) †   0.00     (-0.57, 0.57) 
 
 
4+ Doses (Mean Centered) †   0.00     (-0.02, 0.02) 
 
 
Only 3 Doses (Mean Centered) †  31.76    (-37.68, 178.59) 
 
 
Log of Population Density**   0.00    (-0.46, 0.46) 
 
 
Log of Population Density > age 65** 0.00    (-0.20, 0.20) 
 
 
Percent Black†     -17.64    (-23.37, -11.49) 
 
  
 
 
 
 
For the full list of models tested and their AIC scores, see Table S4 
† Change in odds per 10-percentage point change in PCV7 uptake 
* Odds of a 40-65 year old compared to the odds of a 65+ year old 
**Change in odds per 1 log change in socioeconomic variable 
*** ((Odds Ratio)-1)*100 
  
 
 
 
 
 
 
 
Table 4. Factors associated with having a higher proportion of invasive pneumococcal disease cases caused by a PCV13-  
targeted serotype in ages 40-64 and 65+ combined (Model Averaged).  
                  Variables              Percent Change***  95% CI 
 
Age Category*     -                                      -  
 
 
3+ Doses (Mean Centered) †   0.00     (-0.57, 0.57) 
 
 
4+ Doses (Mean Centered) †   0.00     (-0.02, 0.02) 
 
 
Only 3 Doses (Mean Centered) †  30.94    (-51.12, 250.77) 
 
 
Log of Population Density**   0.00    (-0.51, 0.51) 
 
 
Log of Population Density > age 65** 0.00    (-0.23, 0.23) 
 
 
Percent Black†     22.11    (-28.99, -14.53) 
 
 
 
 
 
For the full list of models tested and their AIC scores, see Table S2 
† Change in odds per 10-percentage point change in PCV7 uptake 
* Odds of a 40-65 year old compared to the odds of a 65+ year old 
**Change in odds per 1 log change in socioeconomic variable 
*** ((Odds Ratio)-1)*100 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Table 5. Factors associated with having a higher proportion of invasive pneumococcal disease cases caused by a PCV13-  
targeted serotype in ages 40-64 (Model Averaged).  
                 Variables          Percent Change***  95% CI 
 
 
 
Age Category*     -                                      -  
 
 
3+ Doses (Mean Centered) †   1.57     (-18.41, 26.45) 
 
 
4+ Doses (Mean Centered) †   0.88               (-12.90, 0.02) 
 
 
Only 3 Doses (Mean Centered) †  1.17    (-34.45, 56.16) 
 
 
Log of Population Density**   -1.51    (-8.92, 6.51) 
 
 
Log of Population Density > age 65** -1.26    (-7.97, 5.93) 
 
 
Percent Black†     -2.79    (-11.24, 6.46) 
 
 
 
 
For the full list of models tested and their AIC scores, see Table S3 
† Change in odds per 10-percentage point change in PCV7 uptake 
* Odds of a 40-65 year old compared to the odds of a 65+ year old 
**Change in odds per 1 log change in socioeconomic variable 
*** ((Odds Ratio)-1)*100 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Factors associated with having a higher proportion of invasive pneumococcal disease cases caused by a PCV13-  
targeted serotype in ages 65+ (Model Averaged).  
Variables       Percent Change***  95% CI 
Table 7. Best model type by age group as determined by weight calculated from AIC score 
 
 
 
 
Age Category Model Type Weight 
 Null 0.0005 
 Mean Change without Secular Trend 0.3956 
<5 Mean Change with Secular Trend 0.1861 
 Slope Change without Secular Trend 0.2831 
 Slope Change with Secular Trend 0.1348 
   
 Null 0.7486 
 Mean Change without Secular Trend 0.0928 
5-17 Mean Change with Secular Trend 0.0444 
 Slope Change without Secular Trend 0.0818 
 Slope Change with Secular Trend 0.0325 
   
 Null 0.0006 
 Mean Change without Secular Trend 0.1221 
18-39 Mean Change with Secular Trend 0.0523 
 Slope Change without Secular Trend 0.5952 
 Slope Change with Secular Trend 0.2298 
   
 Null 0.0005 
 Mean Change without Secular Trend 0.0575 
40-64 Mean Change with Secular Trend 0.1269 
 Slope Change without Secular Trend 0.5488 
 Slope Change with Secular Trend 0.2662 
   
 Null 0.0003 
 Mean Change without Secular Trend 0.2039 
65+ Mean Change with Secular Trend 0.1824 
 Slope Change without Secular Trend 0.3533 
 Slope Change with Secular Trend 0.2599 
 
 
 
 
 
 
 
 
 
FIGURES 
FIGURE 1. Decline in PCV7 and PCV13 serotypes in Connecticut over time. (A) The proportion of 
invasive pneumococcal disease cases caused by PCV7 serotypes in each month and year by age 
group, 1998-2009. (B) The probability that the PCV7-associated decline begins in any given month. 
These distributions can be compared to estimate how long it takes the indirect effect to reach 
unvaccinated age groups.  (C) The proportion of invasive pneumococcal disease cases caused by 
PCV13 serotypes in each month and year by age group, 2006-2013. (D) The probability that the 
PCV13-associated decline begins in any given month. These distributions can be compared to 
estimate how long it takes the indirect effect to reach unvaccinated age groups. The best model type 
(Mean Change without Secular Trend, Mean Change with Secular Trend, Slope Change without 
Secular Trend, Slope Change with Secular Trend) for each age group was used to calculate the 
probability.  
 
FIGURE 2: Uptake of PCV7 among children 12-59 months of age in Connecticut. (A) Average 
uptake of 3+ doses (blue) and 4+ doses (red) of PCV7. (B) Uptake of 4+ doses of PCV7 by ZIP 
Code for all ZIP Codes with at least 20 children per birth cohort. (C) Average uptake of 3+ doses 
(blue) and 4+ doses (red) of PCV13. (D) Uptake of 4+ doses of PCV13 by ZIP Code for all ZIP 
Codes with at least 20 children between 12 and 59 months.  
 
FIGURE 3: (A) Association between uptake of 4+ doses of PCV7 and proportion of IPD cases 
caused by PCV7 serotypes, 2001-2009. (B) Association between uptake of 4+ doses of PCV13 and 
proportion of disease cases caused by PCV13 serotypes, 2010-2013. Each color indicates a different 
calendar year. The bubbles represent quintiles of PCV7 uptake by ZIP Code in each year. The size 
of the bubble is proportional to the number of IPD cases in that strata. 
 
FIGURE 4: Comparison of proportion of IPD cases among 40+ year old adults in a ZIP Code and 
year predicted to be caused by a PCV7 serotype (broken into quintiles by predicted proportion of 
IPD PCV7-targeted adult cases in each year) and the observed proportion in the corresponding 
group. The solid diagonal line denotes where observed=expected. 
 
FIGURE 5: Comparison of proportion of disease cases among 40-64 age group, 65+ age group, and 
combined age group in a ZIP Code and year predicted to be caused by a PCV13 serotype (broken 
into quintiles by predicted proportion of IPD PCV7-targeted adult cases in each year) and the 
observed proportion in the corresponding group. The solid diagonal line denotes where 
observed=expected. 
 
 
FIGURE S1: Mean-centered uptake of PCV7 among children 12-59 months of age in Connecticut, 
by ZIP Code. For each date, the mean value across all ZIP Codes was taken and subtracted from the 
observed uptake value. (A) Mean-centered average uptake of 3+ doses of PCV7. (B) Mean-centered 
uptake of 4+ doses of PCV7. (C) Mean-centered uptake of only 3 doses of PCV7.  All ZIP Codes 
with at least 20 children between 12 and 59 months are shown. 
 
FIGURE S2: Mean-centered uptake of PCV13 among children 12-59 months of age in Connecticut, 
by ZIP Code. For each date, the mean value across all ZIP Codes was taken and subtracted from the 
observed uptake value. (A) Mean-centered average uptake of 3+ doses of PCV13. (B) Mean-
centered uptake of 4+ doses of PCV13. (C) Mean-centered uptake of only 3 doses of PCV13.  All 
ZIP Codes with at least 20 children between 12 and 59 months are shown. 
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